Event Type
Disclosure
Voluntary
Variant
8-K
and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as
Other Events Phase 1 Data for BGE-102 On January 12, 2026, the Company announced additional positive interim Phase 1 data for BGE-102, a novel brain-penetrant N
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by BioAge Labs, Inc. dated January 12, 2026. 104 Cover Page In